Guy P.  Nohra net worth and biography

Guy Nohra Biography and Net Worth

Director of Bioventus

Guy Nohra is a co-founder of Alta Partners, and was also a partner at Burr, Egan, Deleage & Co., which he joined in 1989. Nohra has been involved in the funding and development of notable medical technology and life science companies including ATS Medical, Cutera, Innerdyne, R2 Technology, deCODE genetics, and Vesica.

Previously, Nohra was Product Manager of Medical Products with Security Pacific Trading Corporation. He was responsible for a multi-million dollar product line and traveled extensively in Korea, Taiwan, Hong Kong, China and Southeast Asia.

Currently, Nohra serves on the board of directors of several companies, including AcelRx Pharmaceuticals, Carbylan Biosurgery, PneumRx and Vertiflex, and is the Chairman of the Board of USGI Medical. He also serves on the board of directors of the Medical Device Manufacturing Association (MDMA). He was recently named to the Forbes “Midas List” of dealmakers in high-tech and life sciences. Nohra also serves as the President of the Silicon Valley chapter of The Leukemia and Lymphoma Society.

He holds a Master of Business Administration from the University of Chicago and a Bachelor of Arts in History from Stanford University.

What is Guy P. Nohra's net worth?

The estimated net worth of Guy P. Nohra is at least $1.03 million as of December 4th, 2025. Nohra owns 116,610 shares of Bioventus stock worth more than $1,033,165 as of March 11th. This net worth approximation does not reflect any other assets that Nohra may own. Learn More about Guy P. Nohra's net worth.

How do I contact Guy P. Nohra?

The corporate mailing address for Nohra and other Bioventus executives is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. Bioventus can also be reached via phone at 919-474-6700 and via email at [email protected]. Learn More on Guy P. Nohra's contact information.

Has Guy P. Nohra been buying or selling shares of Bioventus?

Guy P. Nohra has not been actively trading shares of Bioventus in the last ninety days. Most recently, Guy P. Nohra sold 10,000 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $7.57, for a transaction totalling $75,700.00. Following the completion of the sale, the director now directly owns 116,610 shares of the company's stock, valued at $882,737.70. Learn More on Guy P. Nohra's trading history.

Who are Bioventus' active insiders?

Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Michelle Mcmurry-Heath (Director), Guy Nohra (Director), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.

Are insiders buying or selling shares of Bioventus?

In the last twelve months, insiders at the sold shares 6 times. They sold a total of 41,031 shares worth more than $322,332.14. The most recent insider tranaction occured on December, 4th when Director Guy P Nohra sold 10,000 shares worth more than $75,700.00. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.

Information on this page was last updated on 12/4/2025.

Guy P. Nohra Insider Trading History at Bioventus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2025Sell10,000$7.57$75,700.00116,610View SEC Filing Icon  
See Full Table

Guy P. Nohra Buying and Selling Activity at Bioventus

This chart shows Guy P Nohra's buying and selling at Bioventus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bioventus Company Overview

Bioventus logo
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.86
Low: $8.63
High: $8.99

50 Day Range

MA: $8.17
Low: $7.21
High: $9.10

2 Week Range

Now: $8.86
Low: $5.81
High: $11.25

Volume

520,612 shs

Average Volume

292,089 shs

Market Capitalization

$733.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78